Blake Paterson

The American Board of Anesthesiology, Inc. is a voluntary association of lawyers that works to improve the administration of justice and promote programs that assist lawyers and judges in their work. The non-profit company is based in Raleigh, NC. The company also accredits law schools, provide continuing legal education, and work to build public understanding of the importance of the rule of law.

Founded in 1988, Arbor Research & Trading LLC is an institutional research and brokerage firm located in Barrington, Illinois. The firm produces innovative research across a broad range of global fixed-income, equity, currency and commodity markets. In addition, Arbor's trading desk provides comprehensive issue discovery and high quality execution in the fixed-income and currency markets. The firm offers objective viewpoints and intelligent solutions for portfolio managers and traders worldwide through a proprietary menu of independent and innovative research products designed to work in conjunction with clients and their systems.

Part of Pfizer Inc., Parke-Davis & Co. Ltd. is a British pharmaceutical company. The company is based in St. Helier, UK.

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies